Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions

Solid Tumours

Interventions

DRUG

ODM 203

DRUG

ODM 203

Trial Locations (8)

European Institute of Oncology, Milan

Institut Bergonie, Bordeaux

Gustave Roussy Oncology Institute, Villejuif

Finsen Centre, Copenhagen

Helsinki University Central Hospital, Department of Oncology, Helsinki

Vall d'Hebron University Hospital, Barcelona

Sarah cannon Research Institute, London

UCL Cancer Institute, London

All Listed Sponsors

lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT02264418 - Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter